Harvard Apparatus Regenerative Technology Inc. (HRGN)
OQB · Consumer Defensive · Packaged Foods
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Harvard Apparatus Regenerative Technology Inc.
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company's lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. It's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair. The company also sells consumer health products that focuses on personal healthcare, including dietary supplements. Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023. The company was founded in 2009 and is headquartered in Holliston, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 317K | 123K | 219K | 226K |
| Gross Profit | 15K | 11K | 20K | 20K |
| Operating Income | -1.8M | -1.7M | -1.7M | -1.6M |
| Net Income | -1.8M | -1.7M | -1.7M | -1.6M |
| Diluted EPS | $-0.11 | $-0.10 | $nan | $-0.09 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 103K | 430K | 704K |
| Gross Profit | 0.00 | 79K | 160K | 58K |
| Operating Income | -6.2M | -9.0M | -7.7M | -6.9M |
| Net Income | -6.1M | -8.9M | -7.7M | -6.9M |
| Diluted EPS | $-0.55 | $-0.67 | $-0.52 | $-0.42 |